Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3930 - Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC)

Date

08 Oct 2016

Session

Poster Display

Presenters

Jennifer Eads

Citation

Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371

Authors

J. Eads1, S. Stein2, A. El-Khoueiry3, G. Manji4, T. Abrams5, A.A. Khorana6, R. Miksad7, D. Mahalingam8, C. Sirard9, A.X. Zhu10, L. Goyal10

Author affiliations

  • 1 Seidman Cancer Center, University Hospitals Case Medical Center, 44106 - Cleveland/US
  • 2 Cancer Center, Yale University School of Medicine Medical Oncology, New Haven/US
  • 3 Norris Comprehensive Cancer Center, University of Southern Callifornia, Los Angeles/US
  • 4 Division Of Hematology And Oncology, Columbia University, New York/US
  • 5 Gastrointestinal Cancer, Dana Farber Cancer Institute, Boston/US
  • 6 Hematology And Oncology, Cleveland Clinic, Cleveland/US
  • 7 Hematology/oncology, Beth Israel Deaconess Medical Center, Boston/US
  • 8 Cancer Therapy & Research Center, University of Texas Health Science Center San Antonio, San Antonio/US
  • 9 Clinical Research, Leap Therapeutics, Inc., 02141 - Cambridge/US
  • 10 Hematology/oncology, Massachusetts General Hospital, Boston/US
More

Resources

Abstract 3930

Background

DKK1 is an inhibitor of the canonical Wnt/ß-catenin pathway and a modulator of non-canonical signaling. High tissue DKK1 expression in intrahepatic cholangiocarcinoma (CCA) is associated with advanced stage and shorter survival. DKK1 may enhance the invasive properties of CCA, promoting lymph node metastasis by induction of MMP9 and VEGF-C. D has previously demonstrated activity in lung and esophageal cancers. This study evaluated the maximum tolerated dose (MTD), safety and efficacy of D in combination with GC in pts with ABC.

Methods

Patients with histologically confirmed, advanced ABC were eligible. In Part A (3 + 3 design), pts received D at either 150 or 300 mg with G 1000 mg/m2 and C 25 mg/m2 on days 1 and 8 of each 21 day cycle. Part B (300 mg D expansion) has completed enrollment. Response was assessed every 2 cycles using RECISTv1.1.

Results

24 pts were enrolled; 22 pts evaluable for safety; 4 dosed at 150 mg and 18 dosed at 300 mg; 86% screened ABC (21 pts) had DKK1+ tumor tissue. Median age: 65; Female: 68%; White: 86%. Gallbladder cancer 36%, intrahepatic CCA 59%. 3 pts had prior adjuvant G. Median number of cycles: 2 (range 1, 10+); 15 pts still on therapy. No dose limiting toxicities, related serious AEs or treatment emergent adverse events (TEAEs) which lead to discontinuation or dose reduction of D. 13 pts (59%) had grade 3/4 TEAEs; events in ≥ 2 pts include: neutropenia (n = 10), leukopenia, thrombocytopenia (n = 3 each), anemia and AST elevation (n = 2 each). 8 pts (36%) had D-related grade 3/4 TEAEs; events in ≥ 2 pts include: neutropenia (n = 5), thrombocytopenia and AST elevation (n = 2 each). The MTD of D + GC was 300 mg. At the MTD, 9 of 18 patients are evaluable for response; 3 pts had a partial response (PR), 5 pts had stable disease (SD), and 1 pt had progressive disease (PD). Among 4 pts dosed at 150 mg D, 3 pts had SD, 1 pt had PD. Responses and SD have been durable.

Conclusions

Study enrollment is complete. D + GC is well tolerated; safety profile of this regimen appears similar to GC alone. Preliminary data with D (300 mg) + GC demonstrate a response rate of 33% in pts with advanced ABC. Further investigation is ongoing.

Clinical trial identification

NCT02375880.

Legal entity responsible for the study

Jennifer Eads

Funding

Leap Therapeutics, Inc.

Disclosure

J. Eads: Research: BMS. Consulting: ClearView Healthcare Partners. A. El-Khoueiry: Honoraria: BMS, Bayer, Astra Zeneca, Genentech, GSK. Consulting/Advisory Role: BMS, Astra Zeneca, Genentech/Roche. Speakers Bureau: Merimak. Research Funding: Astex. G. Manji: Merck. Research Funding: Conquer Cancer Foundation. Research Funding Ardelyx – Consultant Celgene – Consultant

A.A. Khorana: Janssen, Sanofi, Pfizer, Roche and Halozyme. R. Miksad: corporate sponsored research (to the institution): Bayer, Exelixis, Novartis, Macrogenics. D. Mahalingam: Consulting or Advisory Role - Azaya Therapeutics; Baxalta; Bayer; Dendreon; Genspera; Oncolytics Speakers' Bureau - Bayer; Dendreon.

C. Sirard: Employment - Leap Therapeutics, Inc. Stock and Other Ownership Interests - Leap Therapeutics, Inc. Patents, Royalties, Other Intellectual Property - Leap Therapeutics, Inc.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings